Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA immunogenicity and safety study in at-risk adults 18-49 years versus older adults
jRCT2031240020Phase 3Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 cohorts), sponsored by GSK. Primary endpoints: RSV-A neutralizing antibody geometric mean titer ratio, RSV-A neutralizing antibody seroresponse rate and 2 more. Started May 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240020.